ALMS
$26.21
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the ...
Recent News
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run
Alumis stock: recent performance snapshot Alumis (ALMS) has attracted fresh attention after a period of strong share price moves, including a very large total return over the past year and a solid gain in the past 3 months. The clinical stage biopharmaceutical company focused on autoimmune and neuroinflammatory disorders currently trades around $28.10, with recent returns showing mixed short term moves but sizeable gains over the month and year to date. See our latest analysis for...
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead
Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company’s TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global Healthcare Conference. CEO Martin Babler and CFO John Schroer discussed phase III psoriasis results f
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference
Executives from Alumis (NASDAQ:ALMS) outlined upcoming regulatory milestones and provided additional context around recently announced Phase 3 psoriasis results for envudeucitinib during a fireside chat at Oppenheimer’s Annual Healthcare Conference. Phase 3 psoriasis update: primary endpoint and re
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit
Executives from Alumis (NASDAQ:ALMS) outlined recent clinical results, upcoming regulatory milestones, and pipeline priorities during a discussion at the Guggenheim Emerging Outlook Biotech Summit 2026. Phase III psoriasis data highlights for envudeucitinib President and CEO Martin Babler said Alum
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum
Alumis stock snapshot and recent performance Alumis (ALMS) has drawn fresh attention as its share price closed at US$26.19, with recent returns of 6.9% over the past week, about 46% over the past month, and a very large gain over the past 3 months. See our latest analysis for Alumis. With a 30 day share price return of 46.2%, a very large 90 day share price gain and a 1 year total shareholder return of 361.9%, momentum around Alumis appears to be building as investors reassess its growth...